North America
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
Masashi Miyamoto to be named Chairman and CEO
Abdul Mullick to be named President and COO
Changes designed to further deliver on company’s 2030 Vision and commitment to advancing novel treatments for Bone/Mineral, Intractable Hematological Diseases/Hemato-Oncology and Rare Diseases
Tokyo, 31 October 2024-Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto) today announced that Masashi Miyamoto, Ph.D. will take the role of Chairman and CEO, after serving as President for the past 7 years. Abdul Mullick, Ph.D., the current Chief International Business Officer (CIBO), will become President and Chief Operating Officer. The changes will come into effect following approval at the Ordinary General Meeting of Shareholders and the Board of Directors meeting in March 2025.
These changes reflect a new dual CEO-COO leadership structure to help support the business’ continued growth. Miyamoto, as
31 October 2024
